Enterprise AI Analysis
Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma
This study investigates the correlation between circulating tumor DNA (ctDNA) quantity, assessed via methylated markers, and tumor volume (TV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Utilizing droplet-based digital PCR for HOXD8 and POU4F1 markers and 3D CT scan measurements, the research found a significant correlation between total and liver TV with ctDNA quantity. Specifically, liver metastases TV showed a stronger correlation (Spearman's p=0.500) than total TV (Spearman's p=0.353). A novel finding includes TV thresholds for ctDNA detection, with 90.1 mL for total TV and 3.7 mL for liver metastases TV. These insights suggest ctDNA as a non-invasive surrogate marker, particularly for liver burden, aiding in prognosis and treatment monitoring for mPDAC patients.
Key AI Impact Metrics
Quantifiable insights from the research that highlight potential benefits for your enterprise.
0
ctDNA Detection Rate
0.000
Correlation Total TV vs ctDNA
0.000
Correlation Liver TV vs ctDNA
0
Liver TV Threshold for ctDNA
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
The study used droplet-based digital PCR targeting two methylated markers (HOXD8 and POU4F1) for ctDNA quantity assessment. This method is noted for being rapid, sensitive, fast, and less expensive compared to NGS. The ctDNA detection rate in mPDAC patients was 66.2%, which is comparable to rates reported in the literature using KRAS mutations (46-68%).
Enterprise Process Flow
129 patients
→
123 patients with metastatic tumor
→
120 patients with pancreatic adenocarcinoma
→
115 patients with ctDNA result
→
71 patients with interpretable CT scans
The patient selection process involved several exclusion criteria, including non-metastatic tumors, non-PDAC histological types, missing plasma samples, and uninterpretable CT scans, resulting in a final cohort of 71 patients.
Tumor volume (TV) was measured in 3D from baseline thoraco-abdomino-pelvic computed tomography (CT) scans. This semi-automated method involved segmentation of the primary lesion and metastatic sites (lymph node, liver, peritoneal, lung, adrenal, bone), with verification by a radiologist expert. Lymph nodes were included if the short axis was >15mm.
| Feature | ddPCR (Methylated Markers) | NGS (KRAS Mutations) |
|---|---|---|
| Specificity |
|
|
| Sensitivity |
|
|
| Cost |
|
|
| Speed |
|
|
| Complexity |
|
|
| Prognostic Value |
|
|
| Detection Rate |
|
|
A comparison of ddPCR with methylated markers against NGS with KRAS mutations reveals that ddPCR offers similar sensitivity and prognostic value at a lower cost and faster turnaround time, making it a viable alternative for ctDNA detection.
A significant correlation was observed between total tumor volume (TV) and ctDNA quantity (Spearman's p=0.353, p=0.01). A stronger correlation was found between liver metastases TV and ctDNA quantity (Spearman's p=0.500, p<0.001).
3.7 mL
Liver Metastases TV threshold for ctDNA detection (Sensitivity 85.1%, Specificity 79.2%)
A liver metastases TV threshold of 3.7 mL (corresponding to a spherical lesion of approximately 2 cm in diameter) allowed for ctDNA detection with high sensitivity and specificity. This highlights the particular relevance of liver lesions for ctDNA shedding.
The TV of the primary lesion was not significantly different in patients with detectable or undetectable ctDNA. However, the number and TV of liver metastases were significantly higher in patients with detectable ctDNA. CtDNA was detected in only 9.1% of patients without liver metastasis, versus 76.7% for those with liver metastases, reinforcing the idea that liver metastases are a key contributor to ctDNA burden.
Dynamic Monitoring of ctDNA and TV in mPDAC
For six patients with initially detectable ctDNA and follow-up data, four showed a consistent decrease in ctDNA quantity correlating with a decrease in total TV on evaluation CT scans. However, two patients exhibited discordant evolution, with decreased ctDNA but slight increase in total TV. For three patients with initially undetectable ctDNA, TV decreased on follow-up CT scans, and ctDNA remained undetectable. This suggests that ctDNA dynamics are complex and not always perfectly linear with TV changes.
Impact: While further research is needed, these observations suggest the potential for ctDNA to serve as a valuable tool for dynamic treatment response monitoring, particularly when imaging interpretation is challenging due to post-chemotherapy fibrosis.
Exploratory analysis of follow-up data from six patients revealed mostly consistent trends between ctDNA and TV changes during treatment, with some notable discordances, emphasizing the complexity of ctDNA dynamics and its potential as a complementary monitoring tool.
ctDNA quantification could assist in patient stratification for clinical trials based on tumor volume without time-consuming imaging. For patients with liver metastases and non-contributive initial histological results, liquid biopsy offers a valuable, non-invasive alternative to repeat tissue biopsies, especially when rebiopsy is difficult or delays treatment.
The stronger correlation between ctDNA quantity and liver metastatic TV, coupled with higher ctDNA detection rates in patients with liver metastases, suggests site-specific differences in ctDNA shedding. Possible explanations include high vascularization of the liver and its microenvironment potentially favoring ctDNA release, though more dedicated investigations are warranted.
Given the challenges in accurately measuring pancreatic tumors due to ill-defined margins and desmoplastic stroma, ctDNA offers a non-invasive, complementary approach to evaluate tumor burden, especially in situations where imaging is difficult to interpret post-chemotherapy.
One limitation is the time-consuming nature of 3D TV measurement, especially with numerous lesions (25% of patients had >30 liver metastases). Future development of automated segmentation software and AI could address this. Another limitation is that some patients with high TV had no detectable ctDNA, indicating that factors other than TV contribute to ctDNA detectability, such as tumor differentiation, necrosis, apoptosis, or proximity to vessels.
Quantify Your AI ROI
Estimate the potential efficiency gains and cost savings from implementing AI-driven biomarker analysis in your enterprise operations.
AI Implementation Roadmap
A phased approach to integrating advanced ctDNA analysis into your operational workflow, minimizing disruption and maximizing impact.
Phase 1: Pilot Integration & Data Collection
Integrate ctDNA testing and 3D tumor volume measurement into a pilot cohort. Establish standardized protocols for sample collection, processing, and imaging. Collect baseline and longitudinal data for correlation analysis.
Phase 2: Validation & Threshold Refinement
Validate the observed correlations in larger, multicentric cohorts. Refine TV thresholds for ctDNA detection, particularly for liver metastases, to optimize sensitivity and specificity for various clinical scenarios. Explore factors influencing discordant ctDNA/TV dynamics.
Phase 3: Clinical Trial Integration & Decision Support
Incorporate ctDNA quantification into mPDAC clinical trials for patient stratification and treatment response monitoring. Develop decision support algorithms based on ctDNA and TV data to guide personalized treatment strategies and rebiopsy decisions.
Phase 4: AI-driven Automation & Predictive Modeling
Implement AI-powered automated segmentation for rapid and accurate 3D TV measurement. Develop predictive models that integrate ctDNA, TV, and other clinical factors to forecast patient outcomes and treatment efficacy, enhancing prognostic and predictive capabilities.
Ready to Transform Your Enterprise with AI?
Leverage cutting-edge research to develop bespoke AI strategies. Book a consultation with our experts to discuss your specific needs and unlock new efficiencies.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat